Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX

Affiliation auteurs!!!! Error affiliation !!!!
TitreSafety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
Type de publicationJournal Article
Year of Publication2020
AuteursFumet J-D, Vincent J, Bengrine L, Hennequin A, Granconato L, Palmier R, Ghiringhelli F
JournalANTICANCER RESEARCH
Volume40
Pagination4011-4015
Date PublishedJUL
Type of ArticleArticle
ISSN0250-7005
Mots-clésCapecitabine, Chemotherapy, cisplatin, Docetaxel, Gemcitabine, pancreatic cancer
Résumé

Background/Aim: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX. Patients and Methods: Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX. Results: During this period, 18 patients received PDGX regimen as second-line therapy. Main grade 3 toxicities were hematologic, which required dose adaptation in 14/ 18 patients. No toxic death was observed. Median second-line progression-free survival (PFS) and overall survival (OS) were 2,91 and 5,3 months, respectively. Total OS from the initiation of first-line was and 11,9 months. Conclusion: Second-line PDGX regimen after FOLFIRINOX failure is feasible, with notable toxicity profile and is associated with poor clinical outcomes.

DOI10.21873/anticanres.14395